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Abstract
Translational medicine describes the transfer of basic in vitro and in vivo data into human applications. In the light
of low rates of market approvals for new medical entities, better strategies to predict the risk of drug development
should be used to increase output and reduce costs. Recently, a scoring system to assess the translatability of early
drug projects has been proposed. Here eight drugs from different therapeutic areas have been subjected to a
retrospective test-run in this system fictively located at the phase II-III transition. The scores gained here underline
the importance of biomarker quality which is pivotal to decrease the risk of the project in all cases. This is
particularly evident for gefitinib. The EGFR mutation status is a breakthrough biomarker to predict therapeutic
success which made this compound clinically acceptable, and this is plausibly reflected by a considerable increase
of the translatability score. For psychiatric and Alzheimer’s drugs, and for a CETP-inhibitor, the lack of suitable
biomarkers and animal models is reflected by a low translatability score, well correlating with the excessive
translational risk in these areas. These case studies document the apparent utility of the scoring system, at least
under retrospective conditions, as the scores correlate with the outcomes at the level of market approval.
Prospective validation is still missing, but these case studies are encouraging.
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Introduction
Translational medicine is an important component of
drug development and describes the conditions and pre-
requisites for the transfer of in vitro and in vivo findings
into human applications [1], and should ultimately facil-
itate the development of new drugs. It is hoped that the
“empty pipeline syndrome” (lack of innovation in drug
industry, exceptions granted, e.g. oncology) could be
treated by this (and other) means and the sequelae of
the “patent cliff” (an estimated loss of 150 billion USD
per year in turnover of big pharma companies by patent
expiration within 2-3 years) attenuated.
In the process of drug development several check-
points can be used to evaluate the probable translational
success of a drug project. In 2009 a proposal for the
scoring of the translatability of an early drug project was
presented [2]. The score assesses the availability and
quality of in vitro and in vivo results, clinical data, bio-
markers, and personalized medicine aspects. The
weights given to these different aspects reflect the parti-
cular importance in the translational process. The scores
for the individual items are chosen between 1 and 5 and
multiplied by the weight factors (/100). Any sum score
above 4 is indicative of fair to good translatability and
low risk. The predictive value of biomarkers is assessed
using a special biomarker score which is described in
ref. [3]. The biomarker score is included in the translat-
ability score and comprises the evaluation of biomarkers
in animal and human data, their proximity to the dis-
ease, accessibility and test validity parameters such as
sensitivity and specificity. The use of an additional score
for biomarkers besides the overall translatability score
allows a more detailed analysis of the different facets of
biomarker development, including in vitro data, animal
models, human data, reproducibility etc. especially con-
cerning the particular biomarker while the overall trans-
latability score analyses the whole developmental
process and includes further aspects as model
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compounds and personalized medicine. The importance
of biomarkers in drug development is reflected by the
high weight of this point in the overall translatability
score, and the related biomarker scoring process is an
important part thereof. Thus, this single most important
partial aspect of translatability scoring deserves a struc-
tured approach by itself.
In this work, the two scores were applied to eight
drugs either already approved for the market or failed
during the developmental process. Published data were
retrieved by entering the name of the drug into Medline,
Biosis and Current Contents. All hits were screened for
data applicable to the biomarker and translatability
scores, and literature used for the assessment cited in
the elaborate Tables 1 and 2. Each drug was fictively
assessed after completion of phase II trials (publication
date of references used or first public announcement of
study results prior to the start of phase III as far as
known) to answer the question: at which risk would this
compound be taken to phase III? As an exception, gefi-
tinib, a drug now approved for the treatment of lung
cancer, was also analysed after the demonstration that
an activating EGFR mutation is important for the clini-
cal response which was published shortly after phase III
studies had begun.
Though chosen for this relatively late stage in develop-
ment, the scores should be applied much earlier in pre-
clinical and help to prioritize at this early stage already
[2]. However, for better comparability we fictively chose
the phase II/III transition; case studies at much earlier
stages would have to be done separately.
It is obvious that not all relevant data are present in
the public domain; this limitation of the present study
has to be acknowledged.
Drugs from different therapeutic areas (anticoagula-
tion, cancer, CNS-related diseases, and cardiovascular
disease) have been evaluated. It is obvious that oncology
projects, due to valuable biomarkers, show a much
lower translational risk than candidates in the CNS field
in which reliable, powerful biomarkers (and animal
models) are largely missing.
Case studies
Dabigatran
Dabigatran (marketed as Pradaxa® by Boehringer Ingel-
heim) was approved in the EU for the prevention of
deep vein thrombosis after hip or knee operations in
2008. It is an orally applicable direct thrombin inhibitor
[31,42]. In the present case study the development of
dabigatran for the prevention of strokes in patients with
Table 1 Biomarker scoring for six drugs according to [3]
Points to evaluate Dabigatran Ipilimumab Gefitinib Gefitinib* Vilazodone Latrepirdine Semagacestat
1 5 [4] 3 [5] 5 [6,7] 5 [6-10] 3 [11] - 5 [12,13]
2 5 [4] 1 [5] 3 [6,7,14] 4 [6,7,10,14] 1 [15] - 5 [12,13]
3 3 [16,17] 5 [5] 3 [1] 5 [1] 1 - 3 [18,19]
4 3 [20,21] 2 [5] 5 [1] 5 [1,10,22] 1 - 0 [23]
5 1 5 [5] 5 [24,25] 5 [8,9] 5 [26,27] - 1 [23]
6 10 [20,21] 4 [5] 10 [24,25] 10 [8-10,22,28] 6 [26,27] - 0 [23]
7 4 [29] 5 [5] 4 [30] 5 [28,30] 1 - 1 [23]
8 3 [31] 4 4 5 1 [32] - 5 [33,34]
9 3 [35] 4 4 5 1 [32] - 4
10 5 [36] 5 [1,5] 5 [1] 5 [1] 5 [11] - 4
Sum 42 38 48 54 25 0 0
*after the development of the pivotal biomarker (EGFR mutation status)
The leading biomarkers evaluated were: aPTT for dabigatran, immune related response criteria for ipilimumab, effects on tumor growth for gefitinib, tumor
growth and mutation status of EGFR for gefitinib, Hamilton Rating scale for depression-17 for vilazodone, none for latrepirdine, and effects on amyloid plaques
for semagacestat.
Points to evaluate:
1. Are animal or in vitro data available?
2. How many species have been tested positively?
3. Are the animal models enough to reflect human disease?
4. Is there corresponding clinical data?
5. Are human data available?
6. Human data classification (2x)
7. Does the biomarker represent a pivotal disease constituent?
8. What is the statistical predictability?
9. What is the accuracy or reproducibility of the assay?
10. How accessible is the specimen?
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Table 2 Assessment of translatability for eight drugs according to [2].
Compound Dabigatran Ipilimumab Gefitinib Gefitinib* Vilazodone Latrepirdine Semegacestat Torcetrapib
[37]
Varenicline
[37]
Aspect
Starting evidence
In vitro data Including animal genetics 0.1 [4] 0.06 [38] 0.1 [6,7,39,40] 0.1 [6,7,39,40] 0.08 [41] 0.06 [42-44] 0.1 [12] 0.1 0.1
In vivo data Including animal genetics 0.15 [4] 0.06 [45,46] 0.15 [6,7,14] 0.15 [6,7,14] 0.12 [41,47,48] 0.06 [42,49] 0.15 [12,50] 0.15 0.15
Animal disease models 0.09 [51] 0.06 [1,52] 0.09 [1] 0.09 [1] 0.06
[41,47,48,53]
0.06 [49] 0.03 [18] 0.12 0.15
Data from multiple species 0.15 [4] 0.09 [46] 0.06 [54] 0.06 [54] 0.06 [41,55] 0.03 [42] 0.15 [12] 0.03 0.15
Human evidence
Genetics 0.05 0.05 0.05 0.25 [8-10,22,28] 0.05 0.05 0.25 [56-59] 0.05 0.05
Model Compounds 0.52 [60] 0.52 [61] 0.13 [54] 0.13 [54] 0.65 [62-64] 0.13
[42,43,65,66]
0.13 0.65
Clinical trials 0.52 [31,67] 0.65 [68-74] 0.26 [24,25,75-78] 0.65 [8,9,24,25,75-81] 0.26 [15,82] 0.13 [15,42,83] 0.39 [50,84,85] 0.26 0.52
Biomarkers for efficacy and safety prediction
Biomarker Grading 0.96 [35,36] 0.96 [5] 1.2 [24,25] 1.2 [8,9,24,25] 0.72 [26,27] 0 0 [23] 0.48 1.2
Biomarker development 0.26 0.52 [5] 0.13 [24,25] 0.65 [8-10,22,28] 0.13 [26,27] 0 0 [23] 0.26 0.52
Proof-of-mechanism, proof-of-principle and proof of concept testing
Biomarker strategy 0.2 [35,36] 0.2 [5] 0.05 [24,25] 0.25 [8-10,22,28] 0.15 [26,27] 0 0 [23] 0.1 0.25
Surrogate or endpoint strategy 0.4 0.4 [5] 0.24 [24,25] 0.32 [8-10,22,28] 0.24 [26,27] 0 0 [23] 0.16 0.32
Personalized medicine aspects
Disease sub-classification and responder
concentration
0.12 0.03 0.03 0.15 [8-10,22,28] 0.03 0.03 0.03 0.09 0.03
Pharmacogenetics 0.25 0.05 0.05 0.25 [8-10,22,28] 0.05 0.05 0.05 0.15 0.05
Sum 3.77 3.65 2.54 4.25 2.6 0.60 (0) 1.28 (0) 1.95 4.14
Data for torcetrapib and varenicline are taken from [37].
*after the development of the pivotal biomarker (EGFR mutation status)
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atrial fibrillation (AF) was analysed. The unmet clinical
need for stroke prevention in patients with AF is high,
as the established long-term treatment by vitamin-K-
antagonists (VKA, warfarin, phenprocoumon) is rela-
tively unsafe and difficult to handle. VKA require con-
tinuous monitoring of the coagulation status of the
patient, while dabigatran can be used without routine
monitoring at a fixed dose supporting patient compli-
ance. Another therapeutic option is acetylsalicylic acid,
which is not very effective [86]. Direct thrombin inhibi-
tion in anticoagulation has already been validated and is
the target of the parenteral anticoagulants hirudin and
bivalirudin [60].
No good animal model of atrial fibrillation exists in
general [16,51], but as dabigatran has been proven to
prevent venous thromboembolism, several biomarkers
for the monitoring of coagulation could be used for its
development in the new indication. Activated partial
thromboplastin time (aPTT) has been used as a biomar-
ker of dabigatran effects in several species [4] and clini-
cal trials [31,67]. Consequently, aPTT was assessed in
the biomarker scoring here (Table 1). The correlation of
aPTT with thrombosis and bleeding in a population
with AF had not been clearly established at the time of
the studies; this is reflected in the biomarker score,
especially in items 4 and 5 (low scores of 3 and 1).
Nevertheless, anticoagulation is successful in preventing
stroke in AF [29] and aPTT received a total score of 42
indicating a biomarker of high value for translational
risk prediction (Table 1).
The PETRO study was the first phase II trial which was
conducted to analyse the effect of dabigatran in AF [67].
In the PETRO-EX study the optimal therapeutic dose of
dabigatran was found to be 150 mg twice daily or 300 mg
once daily. The phase III RELY study [87] verified the
results of the phase II trials and was the basis for the
decision of the FDA to approve dabigatran for the stroke
prevention in patients with AF in September 2010.
The development of dabigatran for AF was done at rela-
tively low risk as several features of dabigatran like safety
and the effect on coagulation had already been investi-
gated in earlier studies [31,88]. This is reflected by high
translatability scores for the items model compounds, clin-
ical trials, biomarker grading and surrogates in Table 2.
This case study represents the development of a new ther-
apeutic indication of an already approved drug, which is of
much lower risk than the development of a new drug for a
new application. This lower risk is clearly indicated by the
overall translatability score, which is 3.77 (Table 2) and
therefore indicates mean to fair translatability.
Ipilimumab
Ipilimumab, marketed as Yervoy® by Bristol-Myers
Squibb, is the first therapeutic agent which increases
survival time in patients with metastatic malignant mel-
anoma, the leading cause of death from skin disease
[89]. Previous phase III studies failed to show a survival
benefit [90-92]. Two therapeutic compounds already
approved by the FDA for the treatment of stage IV mel-
anoma, an old chemotherapeutic drug (dacarbazine) and
high dose therapy with the immune stimulant interleu-
kin-2 failed as well [93]. Additionally, high dose inter-
leukin-2 therapy has many adverse effects, so that
excellent cardiovascular and pulmonary functions are
required for its safe use [68,94,95]. Therefore, the unmet
clinical need is high for the treatment of metastatic
malignant melanoma.
Ipilimumab is a fully human monoclonal antibody
(IgG) blocking CTLA-4 (Cytotoxic T-Lymphocyte anti-
gen 4) to promote antitumor immunity. It acts as a
negative regulator of T-cell activation [38]. In vivo stu-
dies showed that blocking CTLA-4/B7 interactions in
murine models induced rejection of different transplan-
table tumors, like colon cancer, prostate cancer, lym-
phoma and renal cancer [96]. In vivo administration of
anti-CTLA-4 antibodies to mice results in rejection of
tumors, including pre-established tumors. Further,
immunity against a secondary exposure to the tumor
was detected [45]. Engagement of CTLA-4 on the sur-
face of activated T-cells by co-stimulatory molecules
inhibits IL-2 and IFNg production upon T-cell receptor
engagement. Blockade of this negative signalling with
CTLA antibodies may result in further activation of acti-
vated T-cells and consequently lead to antitumor activ-
ity [93]. Phase I and II trials showed that ipilimumab is
effective in patients with melanoma [97,68-74].
In a phase II trial, “immune related response criteria”
(irRC) for the evaluation of immune-based cancer thera-
pies were studied [5]. These criteria were newly defined
in a series of workshops on immunotherapeutic agents
in cancer patients. This was inevitable as the criteria
normally used for the evaluation of anticancer therapeu-
tics, the WHO criteria and RECIST (Response evalua-
tion criteria in solid tumors), are not suitable for the
evaluation of immune-based therapies [5]. The clinical
effect of ipilimumab not acting on the tumor itself is
delayed and tumor growth may continue during the first
weeks of treatment. Therefore, the patients seem to
show progressive disease which would be typically
defined as drug failure by the WHO criteria and
RECIST. The newly defined criteria include total tumor
burden, which is calculated by summation of the pro-
duct of the perpendicular diameters of measurable index
lesions, time point assessments, and overall response.
Further, new lesions are taken into account [5]. Evalua-
tion of the irRC using the biomarker score results in the
classification as a medium-high-value marker (score: 38)
(Table 1).
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Immune-response related adverse events frequently
occur in patients treated with ipilimumab, which were
found in all trials [97,68-74]. Diarrhea and colitis as gas-
trointestinal adverse effects, hypophysitis as endocrine
dysfunction, ocular toxicities, and pancreatitis are the
main adverse effects. Despite the high risk of adverse
effects the drug was approved by the FDA in March
2011. In the overall translatability scoring ipilimumab
reaches a score of 3.65, which indicates a mean to fair
translatability (Table 2). The high scores for the newly
developed biomarker (reflected in biomarker grading
and development), for the surrogates, the promising
results in the clinical trials and the high score for model
compounds are the main contributors to this relatively
high score.
Gefitinib
Gefitinib (Iressa®) was approved for treatment of non
small lung cell cancer after failure of docetaxel- or plati-
num-based chemotherapy [98] by the FDA in 2003
under the auspices of the accelerated approval program.
This program gives patients with serious or life-threa-
tening diseases earlier access to promising new drugs.
Gefitinib is a selective reversible inhibitor of the EGFR
(epidermal growth factor receptor) tyrosine kinase
domain and inhibits the anti-apoptotic RAS signal trans-
duction cascade [99]. The drug leads to an increased
survival time in some patients with non small cell lung
cancer [8,9]. The unmet clinical need was high as
patients diagnosed with lung cancer expose a bad prog-
nosis: 5- year survival rate is just 16%.
Several studies showed that the drug only works in
patients with activating mutations in the EGFR
[10,22,28]. 10-15% of the patients in Western countries
show these mutations. 71% of the patients carrying the
mutation respond to treatment, but only 1% of the
patients without this mutation. The responsible muta-
tions include deletions in exon 19 (46%), duplication
and insertion in exon 20 (9%) or point mutations in
exon 21 (39%). Analysis of gene copy numbers of the
EGFR has not consistently shown that this mutation is
also involved in a larger response to gefitinib in the
treatment of non small lung cell cancer after failure of
docetaxel–or platinum-based chemotherapy [10,22,98].
The dependence of the efficacy of gefitinib on the muta-
tion status was detected by in vivo and in vitro studies
[10] after the start of phase III trials. Consequently, the
failure of the first phase III trials (INTACT I [79] and II
[80]) was due to a comparatively low rate of patients
with EGFR mutations. In the ISEL trial [81] also no
increase of overall survival time was detected, but a sub-
study revealed that neversmokers had an increased sur-
vival time (8.5 vs 5.5 months). This effect was even
greater in patients of Asian origin (9.5 vs 5.5 months).
Asian populations have much higher rates of EGFR acti-
vating mutations. In response, the FDA revoked the
accelerated approval of 2003 in 2005, and limited the
indication to patients who were already on the drug and
had benefited from it. In the INTEREST trial [8] the
impact of activating EGFR mutations was clinically
shown by a significantly higher response rate (42.1 vs
21.1%). Accordingly, the IPASS study [9] on Asian
patients demonstrated a higher response rate for gefiti-
nib versus standard therapy and patients without the
mutation did not respond to gefitinib. The EMEA
approved gefitinib for the treatment of non small cell
lung cancer for patients carrying an activating EGFR
mutation in 2009.
In the evaluation of these studies the inclusion of the
EGFR mutation status into the biomarker panel
improved the overall translatability score from 2.54 to
4.25 (Table 2). This increase reflects higher individual
scores for biomarker grading, biomarker development,
strategy, clinical trials and personalized medicine items.
The biomarker score alone would predict a high trans-
latability also for the use of tumor growth as this is a
widely used biomarker. Only the translatability score
considers the importance of the mutation. This case
clearly shows that the use of both scoring systems is
important to more accurately predict success of the par-
ticular project. As already mentioned, gefitinib is an
example of a drug in which personalized medicine
aspects play a pivotal role for the responder rates.
Instead of being a blockbuster with an indication for all
lung cancer patients, gefitinib is only effective in 10-15%
of the patients in Western countries. The company
decided to push the compound before personalized
medicine issues had been solved which were likely to
exist. Therefore, the blockbuster-type approach was
doomed to fail. The case of gefitinib is a good example
for the trend to use more genetic biomarkers to aid per-
sonalization instead of the development of block buster
drugs in the field of oncology (and elsewhere). Addition-
ally, the development of companion diagnostics is an
important field of drug development, underlining the
importance of biomarkers again, especially in oncology.
Therefore the item for personalized medicine in this
field is of great importance and may eventually be
weighted higher in oncology.
Vilazodone
Vilazodone (5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-pipera-
zinyl)-benzofuran-2carboxamide hydrochloride) was
approved by the FDA in January 2011 for the treatment
of major depressive disorder and is marketed as Vii-
bryd® by Clinical Data Inc. Despite the availability of
approved drugs for the treatment of major depressive
disorder, many patients do not adequately respond to
Wendler and Wehling Journal of Translational Medicine 2012, 10:39
http://www.translational-medicine.com/content/10/1/39
Page 5 of 11
these therapies and therefore new, more effective drugs
are needed. Recent experiments have shown that the
administration of 5HT1A (5-hydroxytryptamine) antago-
nists augments the effects of SSRIs on extracellular 5-
HT [100,101]. Vilazodone is a selective serotonin reup-
take inhibitor (SSRI) (IC50 = 0.2 nM) and a 5-HT1A
receptor partial agonist (IC50 = 0.5 nM; IA = ~60-70%)
[41,55].
For a number of reasons, the development of drugs
acting at the CNS carries a greater translational risk
than, for instance, the development of drugs against
malignancies. These reasons include that
i) the animal models used to analyse the effect of
drugs in psychiatric disease (shock probe test, predator
stress model, forced swimming test, ultrasonic vocalisa-
tion model in rodents) are not very effective to predict
drug efficacy in patients,
ii) biomarkers used in patients with major depressive
disorder (Hamilton rating scale for depression, Mon-
tgomery-Asberg Depression rating scale, Clinical Global
Impressions Improvement, Hamilton Anxiety Rate
Scales) are weak and can only be used in patients, but
not in animals.
Thus, these biomarkers are not potent to predict risk
at early stages of drug development. Further, their statis-
tical predictability and reproducibility are not high [32].
In consequence, the translational score for CNS drugs is
low in most cases and such projects remain at high risk.
Vilazodone was evaluated in five phase II randomized,
placebo-controlled studies in patients with major
depressive disorder by Merck and GlaxoSmithKline.
Three of the trials used active comparators and all
employed the Hamilton Rating Scale for Depression-17
(HAM-D17) [11] as primary outcome [15]. Therefore
this scale was also used in the biomarker scoring in this
work (score: 25, Table 1). The three studies that had an
active control failed to show superiority and the remain-
ing two studies were negative (http://www.accessdata.
fda.gov/drugsatfda_docs/nda/2011/022567Orig1-
s00CrossR.pdf). Despite these negative results Clinical
Data Inc. obtained an exclusive license and showed sta-
tistically significant efficacy against placebo in a phase
III trial [102]. Further biomarkers to predict therapeutic
efficacy were developed (key genes in the 5-HT path-
way) (reviewed in [103]). However, the biomarkers failed
to show an association with the response to vilazodone
in a second phase III trial. The biomarker have not been
published yet; they are not used to identify responders
as it has been shown that vilazodone is beneficial to a
broader group of patients than defined by the use of
these biomarkers [103].
Despite the failure of the phase II trials and the weak
biomarker profile of this project the drug was finally
approved after the two successful phase III studies.
Vilazodone belongs to the widely used class of SSRIs
and therefore shows the characteristics of the develop-
ment of a “me too” compound, which is reflected by the
high score for model compounds in the overall translat-
ability score. The new feature of a 5-HT1A receptor par-
tial agonist increases the translatability of this project
since it was already shown that combining pindolol, a
mixed 5HT1A/ß-adrenergic receptor partial agonist,
with SSRIs enhances the increase of extracellular levels
of 5-HT in preclinical studies [62] and produces a more
rapid onset of antidepressive effects [63,64]. Further,
compared to other SSRIs on the market, vilazodone
shows less impairment of sexual function [15]. Despite
the characteristics of a me-too compound, the score for
overall translatability of vilazodone indicates a poor to
intermediate translatability and, thus, comparably high
risk (score: 2.6, Table 2) due to the lack of powerful bio-
markers in this field. This example shows that even me-
too compounds may have a high translatability risk if
powerful biomarkers are missing. Despite this low score,
the compound was finally approved against all odds and
shows that even low score projects may eventually be
successful. The item on model compounds in the trans-
latability score was ranked high; this fact may be taken
as a starting point for the improvement of the scoring
tool in that the weighing of model compounds should
be even higher than in the present algorithm.
Latrepirdine
Latrepirdine (2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-
methyl3-pyridinyl)ethyl]-1H-pyrido[4,3-b] indole, pro-
vided as the dihydrochloride salt) was formerly used as
antihistaminic drug and marketed as Dimebon® [42],
but was removed from the market due to the develop-
ment of more selective drugs in the field. Recently it
was evaluated as a drug against Alzheimer’s disease
(AD). The unmet clinical need is high for new drugs
against AD as no efficient causal treatment exists so far
[104]. The major problem in the development of drugs
against AD seems to be the lack of knowledge about the
exact pathogenetic mechanisms resulting in AD.
Latrepirdine was shown to act as a cholinesterase and
NMDA inhibitor, the two mechanisms of action of
existing symptomatic AD drugs [42,43,65]. Newer stu-
dies have demonstrated that its primary action in AD
relates to the stabilization of mitochondrial function.
Evidence from in vitro studies suggests that latrepirdine
might protect against amyloid-b(Aß)-mediated toxicity
in primary neuron cultures and improve mitochondrial
function in cultured cells [42-44]. However, it is unclear
whether latrepirdine can exert a disease-modifying activ-
ity in vivo and improve AD neuropathology and/or clini-
cal symptoms in animal models of AD. In contrast to
many other AD drugs in the pipeline, latrepirdine’s
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action is not based on the reduction of amyloid plaques.
The importance of plaque formation in AD is contro-
versially discussed, and the opinion that the overproduc-
tion and accumulation of Ab in the brain are key
pathogenic events in AD progression is increasingly
questioned [105]. Concerning the disease modifying
activity of latrepirdine no data are available from the dif-
ferent clinical trials as only the 11-item ADAS-cog was
used as primary outcome. The 11-item ADAS-cog is
only available at the human level and risk assessment at
early stages is hampered by the lack of appropriate ani-
mal biomarkers and animal models. In the clinical trials
no biomarker for the disease modifying action has been
used. Therefore, biomarker grading and strategy repre-
sent knock-out criteria in the overall translatability scor-
ing (Tables 1 and 2) supporting a no-go decision at an
early stage of development. This example supports the
view that biomarkers are the single most important
parameter for go/no-go decision at the transition from
preclinical to clinical and early clinical to late phase
where the weight is more on clinical and safety biomar-
kers and the overall strategy for their use.
As latrepirdine had been available as antihistaminic
drug several years ago, its safety profile seemed to be
established. Phase I [42] and II [83] trials were encoura-
ging as latrepirdine improved the clinical course of the
patients. Surprisingly, in the subsequent phase III trial
the drug failed to show a significant effect compared to
placebo [106].
The failure of this drug was likely (translatability score
0.6, or 0 if knock-out is accepted) as the pathogenetic
mechanisms are not understood for AD and no power-
ful biomarkers exist. Using the scores during the devel-
opmental process of the drug might have prevented the
expenditures for its late clinical development. The pri-
mary development of a biomarker to assess the disease
progression and its therapeutic modification would be
important, but requires knowledge about AD pathogen-
esis and the way of action of latrepirdine in AD.
Semagacestat
Semagacestat is a gamma-secretase inhibitor and inhibits
the final step in Aß-protein synthesis as putative target
for AD treatment. Therefore, unlike latrepirdine the
mode of action is known for semagacestat. The mole-
cule rapidly reduces Ab concentrations in the brain, cer-
ebrospinal fluid (CSF), and plasma of transgenic V717F
human amyloid precursor protein mice (PDAPP mice)
[12] and in the plasma of humans [13]. In the develop-
ment of semagacestat amyloid plaques have been used
as biomarker like in many other AD studies. Until now,
all other studies based on this biomarker failed support-
ing the assumption that measuring the formation of pla-
ques is insufficient to predict therapeutic success. The
importance of plaque formation in AD is controversially
discussed, and the opinion that the overproduction and
accumulation of Ab in the brain are key pathogenic
events in AD progression is increasingly questioned
[105]. Accordingly, plaques can be reduced by semaga-
cestat, but the symptoms are not improved in treated
AD patients. The plaques might be useful to identify
patients with AD [107] (disease indicator), but they are
no valuable tool to predict treatment success (disease
factors). Additionally, imaging methods to detect the
plaques are quite expensive [108]. Therefore the scoring
for plaques as biomarkers contains knock-out features
for corresponding clinical data and human data classifi-
cation and is rated at 0 in the overall translatability
score (Tables 1 and 2). Additionally, skin cancer was
observed as a severe adverse effect of the treatment with
semagacestat; cognitive function even worsened in the
phase III trial.
Semagestat is another example of a failed drug devel-
opment in the AD field, with a high risk translatability
score of 1.28 (or 0 if the knock-out criterion is
accepted).
The major implication of the assessment of these two
potential AD drugs is the fact that the etiology of AD is
not yet understood and Aß targeted therapies are likely
to attack an epiphenomenon. This gap of knowledge is
mainly reflected by the lack of a biomarker placed more
proximal in AD etiology. Further studies are needed to
analyse the pathogenesis of the disease and to develop
suitable biomarkers.
The Coalition Against Major Diseases (CAMD) has
released a database on 4,000AD patients who have parti-
cipated in 11 industry-sponsored failed clinical trials.
Publishing of negative trial results is important to pre-
vent further trials from failing and is an important
achievement in the development of drugs against AD.
Two further drugs (torcetrapib and varenicline) have
been scored for translatability in a recent publication
[37]; the related scoring items are cited here for com-
parison and the widening of the spectrum of therapeutic
areas.
Torcetrapib
Torcetrapib was developed to treat hypercholesteria and
prevent cardiovascular disease. It inhibits cholesteryl
ester transfer protein (CETP) resulting in increased con-
centrations of HDL-cholesterol (’good cholesterol’).
CETP inhibitors increased HDL-levels in various animal
models and early human trials, and could even prevent
diet-induced atherosclerosis in NZW rabbits, albeit not
in other animal models. The development of torcetapib
was based on the hypothesis that an intervention leading
to increased levels of HDL-cholesterol should be benefi-
cial for the patients. It is now known that the use of
Wendler and Wehling Journal of Translational Medicine 2012, 10:39
http://www.translational-medicine.com/content/10/1/39
Page 7 of 11
HDL as a biomarker was too positive and other biomar-
kers like intima-media thickness should have been used
to predict efficacy to prevent cardiovascular disease. The
test-run of the scoring proposal at a fictive knowledge
status prior to the ILLUSTRATE results produces a sum
score of 1.95 (Table 2), clearly indicating a high-risk
translational project [37].
Varenicline
Varenicline is a novel drug to aid smoking cessation and
was developed by Pfizer. The drug partially agonizes the
nicotinic receptor and, thus, reduces craving for smoking.
As receptors are occupied, a new cigarette respectively
the nicotine contained is ineffective ("antagonized”).
The translational evidence was based on isolated
receptor subtypes cloned from animals and humans and
on valid animal models for nicotine dependence and
nicotine side effects (e.g. hypothermia). These are absent
in limited ceiling effects of partial agonists. Biomarkers
at the animal level (behavioural measures) and compar-
ably simple clinical studies on smoking habits and psy-
chometric scales for craving and satisfaction had been
established and validated at the time of varenicline
translation. This included the use of model compounds
(especially bupropion). The fictive translatability score
prior to the pivotal Phase III trials was 4.14, indicating a
high likelihood of translational success [37].
Conclusions and outlook
The overall translatability score awaits validation. The
present work demonstrates that the scoring process see-
mingly produces plausible results retrospectively which
is encouraging. The scoring system clearly shows that
the early development and use of powerful biomarkers
considerably decreases the risk in drug development. In
general, stronger biomarkers exist to develop drugs
against malignant than CNS diseases.
All limitations of retrospective analyses apply to the
case studies, and biases in the scoring of the individual
items reflecting the final drug approval status cannot be
excluded. Careful referencing and, thus, transparency of
decisions are important in this process. The results and
their open traceability together with plausible results
should encourage industry and–perhaps–even public
funding agencies to plan and finance a prospective vali-
dation study. Unfortunately, this study would probably
take a decade to produce valuable results as drug devel-
opment cycles require that much time. Nevertheless, the
system already now appears as a valuable tool to calcu-
late the risk of a current drug development project.
Further, the scores provide guidance to identify weak-
nesses and opportunities in drug development and, thus,
may lead to strategy adjustments, with the pre-emptive
development of biomarkers as a prominent example.
The score carries all features of likelihood determina-
tions, and a low translatability score does not preclude
success (as for vilazodone), and a high score does not
guarantee it either. It should not be seen as a static
model, but needs to be developed and adapted to differ-
ent therapeutic areas; for example, the item on persona-
lized medicine should be weighed higher in oncology
than cardiovascular medicine. As mentioned above, the
weight for model compounds should be reconsidered
and–depending on the therapeutic area–probably
increased.
Therefore, as a future task scoring parameters and
weights should be adjusted according to the compound
class and the targeted system pathways. Due to the high
diversity of drugs developments in different diseases, the
score must be flexible and dynamic to be applicable to
most situations. The validation and adaptation of the
score might be best placed in a pre-competitive environ-
ment such as a consortium of researchers from big
pharmaceutical companies.
Though the individual items and weight factors might
be debatable, the major impact of the scoring process as
such should be seen in the establishment of a structured
profiling and transparent, vigorously scientific, objective
reasoning as opposed to an irreproducible, subjective
and unstructured “gut-feeling” decision taking. The
metric values seem less important than the structuring
potential of this approach.
As a second important aspect discussed in detail in [2]
the scoring at the early phase identifies weaknesses of a
given project at an early stage and, thereby, may strate-
gically help to define the need of particular clinical stu-
dies for sufficient proof, may indicate the need for the
development of companion diagnostics or rigorous
patient stratification. These strategies would then aim at
improving weak scores at the first instance, but ulti-
mately more important, help to reduce risks. This will
be part of the evaluation of costs, risks and ROI to
make go/no-go decisions in a qualified way.
In conclusion, eight retrospective case studies of trans-
latability scoring produced scores which are in line with
success or failure as project outcome, underlining the
plausibility and utility of the approach. The score should
be developed, adapted and prospectively validated.
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